chevrons

Back to Previous Page

Company Quarterly Earnings Update – DHG VN – 2018 Q3

Summary of the 9M 2018 results of Hau Giang Pharmaceutical JSC (DHG VN) 

9M/2018 results: highlights
  • Net revenue was VND 2,669 bn, -1.5% y/y. Own product revenue (83% of total revenue) grew by 6% y/y, while the remainder of DHG’s revenue declined by 20% y/y because of the dropout of trading medicine revenue. DHG removed the trading medicine business line in order to be qualified for the foreign ownership limit (FOL) lifting.
  • Profit before tax amounted to VND 512 bn, +3.2% y/y, growing faster than revenue thanks to improved efficiency and thus lower operating expenses. The bottom line was however down by 9.9% y/y as the company paid most  of its 2017 taxes in Q4 due to last year’s tax dispute. This year, tax expenses were distributed more evenly among the quarters.
  • DHG’s financial position remained solid with a large amount of liquid assets (cash and deposits made up 37.6% of total assets) and a low leverage (D/E and D/A of 0.21x and of 0.15x respectively).
Other developments
  • The FOL was fully lifted from 3 Jul 2018. Thereafter, Taisho Pharmaceutical Co., Ltd. increased its stake to 34.3% after making a tender offer for a 7.0% stake at a price of VND120,000/share; afterwards, Taisho purchased an additional 2.3% stake through the open market.
Outlook
  • DHG’s prospects remain bright thanks to strong demand for reasonably priced generic drugs (IQVIA estimates a CAGR of 9% during 2017-2021). What is more, the recent launch of some skincare products in cooperation with Taisho’s partners have opened the cosmetics and the supplements market. However, cosmetics currently account for less than 10% of DHG’s revenue.
  • The 2018 and the 2019 bottom lines are estimated to reach VND 674 bn (+4.8% y/y) and 741 bn (+9.9% y/y) respectively.
Recommendation

Company ratings and target prices are accessible for clients only.

If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.

Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.

 

Featured image credit: ndh.vn

 

Related News & Insights
Find out more navigation_button
news

Summary of H1 2025 results and outlook of VPBank (VPB VN) Net income surged 22.8% y/y, fueled by accelerated credit expansion and continued sharp enhancement in asset quality. Total credit grew 30.3% y/y, driven by strong demand across diversified corporate sectors, as well as various retail segments including consumption, mortgages, and margin lending. Net interest […]

Read Newsarrow
news

Summary of Q2 2025 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN) Net revenue rose 12.1% y/y to VND916 billion. By product category, the three strategic segments—Antibiotics (+14.8% y/y), Oncology (+13.8% y/y), and Dialysis solutions (+30.9% y/y)—together accounted for 63.5% of total sales. By distribution channel, the hospital segment, which […]

Read Newsarrow
news

Summary of Q2 2025 results and outlook of Binh Minh Plastics JSC (BMP VN) Net revenue reached VND2,691bn (+24.8% y/y), driven by a 25.5% y/y increase in sales volume. Growth was supported by an early recovery in real estate construction and the front-loaded timing of promotional campaigns (held in Q1 and end-Q2 vs. Q3 in […]

Read Newsarrow
Find out more navigation_button